2 research outputs found
Corrigendum to “Cellular landscaping of cisplatin resistance in cervical cancer” Biomed. Pharmacother. 153(2022) 113345 (Biomedicine & Pharmacotherapy (2022) 153, (S075333222200734X), (10.1016/j.biopha.2022.113345))
No full textPublisher Copyright: © 2024 The AuthorsThe authors regret that incorrect information was given in the citation list of the publication The incorrect references and their corrections are as follows: Reference 27 should be same as reference 245 Reference 75 should be same as reference 82 Reference 274 should be same as reference 276 Reference 53 should be: Li, Q., Peng, X., Yang, H., Rodriguez, J. A., & Shu, Y. (2012). Contribution of organic cation transporter 3 to cisplatin cytotoxicity in human cervical cancer cells. Journal of pharmaceutical sciences, 101(1), 394–404. Reference 61 Should be: Waalkes, M. P., Liu, J., Kasprzak, K. S., & Diwan, B. A. (2006). Hypersusceptibility to cisplatin carcinogenicity in metallothionein-I/II double knockout mice: Production of hepatocellular carcinoma at clinically relevant doses. International journal of cancer, 119(1), 28–32. https://doi.org/10.1002/ijc.21245 References 69, and 73 should be: Wang, N., Hou, M. S., Zhan, Y., Shen, X. B., & Xue, H. Y. (2018). MALAT1 promotes cisplatin resistance in cervical cancer by activating the PI3K/AKT pathway. European Review for Medical & Pharmacological Sciences, 22(22). Reference 96 should be: Chen SH, Chang JY. New Insights into Mechanisms of Cisplatin Resistance: From Tumor Cell to Microenvironment. Int J Mol Sci. 2019 Aug 24;20(17):4136. doi: 10.3390/ijms20174136 Reference 229 should be: O′Brien, J., Hayder, H., Zayed, Y., & Peng, C. (2018). Overview of microRNA biogenesis, mechanisms of actions, and circulation. Frontiers in endocrinology, 9, 402. Reference 247 should be: Schräder, M., Nayeri, S., Kahlen, J. P., Müller, K. M., & Carlberg, C. (1995). Natural vitamin D3 response elements formed by inverted palindromes: polarity-directed ligand sensitivity of vitamin D3 receptor-retinoid X receptor heterodimer-mediated transactivation. Molecular and cellular biology, 15(3), 1154–1161. References 4, 156, 180, 199, 270, 273, are unnecessary and can be deleted The authors would like to apologise for any inconvenience caused.Peer reviewe
Cellular landscaping of cisplatin resistance in cervical cancer
No full textPublisher Copyright: © 2022 The AuthorsCervical cancer (CC) caused by human papillomavirus (HPV) is one of the largest causes of malignancies in women worldwide. Cisplatin is one of the widely used drugs for the treatment of CC is rendered ineffective owing to drug resistance. This review highlights the cause of resistance and the mechanism of cisplatin resistance cells in CC to develop therapeutic ventures and strategies that could be utilized to overcome the aforementioned issue. These strategies would include the application of nanocarries, miRNA, CRIPSR/Cas system, and chemotherapeutics in synergy with cisplatin to not only overcome the issues of drug resistance but also enhance its anti-cancer efficiency. Moreover, we have also discussed the signaling network of cisplatin resistance cells in CC that would provide insights to develop therapeutic target sites and inhibitors. Furthermore, we have discussed the role of CC metabolism on cisplatin resistance cells and the physical and biological factors affecting the tumor microenvironments.Peer reviewe
